Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Main Authors: | Pavord, I, Kerstjens, H, Korn, S, Criner, G, Sagara, H, Rubin, D, Harris, S, Mayer, B, Bradford, E, Albers, F, Yancey, S |
---|---|
Format: | Conference item |
Published: |
European Respiratory Society
2017
|
Similar Items
-
Mepolizumab for eosinophilic chronic obstructive pulmonary disease
by: Pavord, I, et al.
Published: (2017) -
Mepolizumab for eosinophilic COPD
by: Sciurba, F, et al.
Published: (2018) -
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
by: Bafadhel, M, et al.
Published: (2018) -
Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
by: Gunsoy, N, et al.
Published: (2017) -
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
(COPD): A Meta-Analysis of METREX and METREO Patient-Reported
Outcomes, Response to Therapy and Lung Function
by: Chapman, K, et al.
Published: (2018)